Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 7.2% – Time to Sell?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was down 7.2% during trading on Tuesday . The company traded as low as $0.28 and last traded at $0.29. Approximately 30,458,623 shares were traded during trading, a decline of 56% from the average daily volume of 68,841,906 shares. The stock had previously closed at $0.31.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on shares of Tonix Pharmaceuticals in a research note on Thursday. They issued a “hold” rating for the company.

Tonix Pharmaceuticals Trading Down 11.1 %

The stock has a market cap of $47.84 million, a PE ratio of 0.00 and a beta of 2.02. The company has a 50 day moving average of $0.25 and a two-hundred day moving average of $0.33. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($2.03) by $1.80. The business had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. Sell-side analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current fiscal year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.